Frontotemporal lobar degeneration (FTLD) is a progressive neurodegenerative syndrome. Defects of copper (Cu) and iron (Fe) homeostasis are involved in the development of several neurodegenerative diseases and their homeostasis is interconnected by the Cu-protein ceruloplasmin (Cp), responsible for Fe oxidative state. In this study we assessed Fe, transferrin (Trf), ferritin, Cp specific activity (eCp/iCp), Cp/Trf ratio, and Trf saturation in 60 FTLD patients and 43 healthy controls, and discussed the results in relation to Cu homeostasis. The significant decrease of the eCp/iCp in the FTLD patients supports the involvement of Fe imbalance in the onset and progression of FTLD.
MackenzieIR, NeumannM, BaborieA, SampathuDM, Du PlessisD, JarosE, PerryRH, TrojanowskiJQ, MannDM, LeeVM (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol122, 111–113.
11.
MackenzieIR, NeumannM (2012) FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis. Brain Res1462, 40–43.
12.
BandmannO, WeissKH, KalerSG (2015) Wilson’s disease and other neurological copper disorders. Lancet Neurol14, 103–113.
13.
LiDD, ZhangW, WangZY, ZhaoP (2017) Serum copper, zinc, and iron levels in patients with Alzheimer’s disease: A meta-analysis of case-control studies. Front Aging Neurosci9, 300.
14.
SquittiR, VentrigliaM, GennarelliM, ColabufoNA, El IdrissiIG, BucossiS, MarianiS, RongiolettiM, ZanettiO, CongiuC, RossiniPM, BonviciniC (2017) Non-ceruloplasmin copper distincts subtypes in Alzheimer’s disease: A genetic study of ATP7B frequency. Mol Neurobiol54, 671–681.
15.
VentrigliaM, BucossiS, PanettaV, SquittiR (2012) Copper in Alzheimer’s disease: A meta-analysis of serum, plasma, and cerebrospinal fluid studies. J Alzheimers Dis30, 981–984.
16.
WangZX, TanL, WangHF, MaJ, LiuJ, TanMS, SunJH, ZhuXC, JiangT, YuJT (2015) Serum iron, zinc, and copper levels in patients with Alzheimer’s disease: A replication study and meta-analyses. J Alzheimers Dis47, 565–581.
17.
HouseE, CollingwoodJ, KhanA, KorchazkinaO, BerthonG, ExleyC (2004) Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer’s disease. J Alzheimers Dis6, 291–301.
18.
SmithMA, HarrisPL, SayreLM, PerryG (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A94, 9866–9868.
19.
TellingND, EverettJ, CollingwoodJF, DobsonJ, van der LaanG, GallagherJJ, WangJ, HitchcockAP (2017) Iron biochemistry is correlated with amyloid plaque morphology in an established mouse model of Alzheimer’s disease. Cell Chem Biol24, 1205–1215e1203.
20.
SquittiR, FostinelliS, SiottoM, FerrariC, BinettiG, BenussiL, RongiolettiM, GhidoniR (2018) Serum copper is not altered in frontotemporal lobar degeneration. J Alzheimers Dis63, 1427–1432.
21.
De ReuckJL, DeramecourtV, AugerF, DurieuxN, CordonnierC, DevosD, DefebvreL, MoreauC, Caparros-LefebvreD, LeysD, MaurageCA, PasquierF, BordetR (2014) Iron deposits in post-mortem brains of patients with neurodegenerative and cerebrovascular diseases: A semi-quantitative 7.0 T magnetic resonance imaging study. Eur J Neurol21, 1026–1031.
22.
GazzinaS, PremiE, ZanellaI, BiasiottoG, ArchettiS, CossedduM, ScarpiniE, GalimbertiD, SerpenteM, GasparottiR, PadovaniA, BorroniB (2016) Iron in frontotemporal lobar degeneration: A new subcortical pathological pathway?Neurodegener Dis16, 172–178.
23.
HigginsT (1981) Novel chromogen for serum iron determinations. Clin Chem27, 1619–1620.
24.
CookJD, DassenkoS, SkikneBS (1990) Serum transferrin receptor as an index of iron absorption. Br J Haematol75, 603–609.
25.
SkikneBS, FlowersCH, CookJD (1990) Serum transferrin receptor: A quantitative measure of tissue iron deficiency. Blood75, 1870–1876.
GiambattistelliF, BucossiS, SalustriC, PanettaV, MarianiS, SiottoM, VentrigliaM, VernieriF, Dell’acquaML, CassettaE, RossiniPM, SquittiR (2012) Effects of hemochromatosis and transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer’s disease. Neurobiol Aging33, 1633–1641.
28.
LehmannHP, SchosinskyKH, BeelerMF (1974) Standardization of serum ceruloplasmin concentrations in international enzyme units with o-dianisidine dihydrochloride as substrate. Clin Chem20, 1564–1567.
29.
SchosinskyKH, LehmannHP, BeelerMF (1974) Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin Chem20, 1556–1563.
30.
SiottoM, PasqualettiP, MaranoM, SquittiR (2014) Automation of o-dianisidine assay for ceruloplasmin activity analyses: Usefulness of investigation in Wilson’s disease and in hepatic encephalopathy. J Neural Transm (Vienna)121, 1281–1286.
31.
BisagliaM, BubaccoL (2020) Copper ions and Parkinson’s disease: Why is homeostasis so relevant?Biomolecules10, 195.
32.
De BenedictisCA, VilellaA, GrabruckerAM (2019) The role of trace metals in Alzheimer’s disease. In Alzheimer’s Disease,
WisniewskiT, ed., Brisbane (AU).
WeilandA, WangY, WuW, LanX, HanX, LiQ, WangJ (2019) Ferroptosis and its role in diverse brain diseases. Mol Neurobiol56, 4880–4893.
35.
BielliP, CalabreseL (2002) Structure to function relationships in ceruloplasmin: A ‘moonlighting’ protein. Cell Mol Life Sci59, 1413–1427 .
36.
SiottoM, SimonelliI, PasqualettiP, MarianiS, CapraraD, BucossiS, VentrigliaM, MolinarioR, AntenucciM, RongiolettiM, RossiniPM, SquittiR (2016) Association between serum ceruloplasmin specific activity and risk of Alzheimer’s disease. J Alzheimers Dis50, 1181–1189.
37.
BrewerGJ, KanzerSH, ZimmermanEA, CelminsDF, HeckmanSM, DickR (2010) Copper and ceruloplasmin abnormalities in Alzheimer’s disease. Am J Alzheimers Dis Other Demen25, 490–497.
38.
TorsdottirG, KristinssonJ, SnaedalJ, JohannessonT (2011) Ceruloplasmin and iron proteins in the serum of patients with Alzheimer’s disease. Dement Geriatr Cogn Dis Extra1, 366–371.
39.
KristinssonJ, SnaedalJ, TorsdottirG, JohannessonT (2012) Ceruloplasmin and iron in Alzheimer’s disease and Parkinson’s disease: A synopsis of recent studies. Neuropsychiatr Dis Treat8, 515–521.
40.
LiJ, CaoF, YinHL, HuangZJ, LinZT, MaoN, SunB, WangG (2020) Ferroptosis: Past, present and future. Cell Death Dis11, 88.
41.
LaneDJR, AytonS, BushAI (2018) Iron and Alzheimer’s disease: An update on emerging mechanisms. J Alzheimers Dis64, S379–S395.
42.
HambrightWS, FonsecaRS, ChenLJ, NaR, RanQT (2017) Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biol12, 8–17.
43.
Do VanB, GouelF, JonneauxA, TimmermanK, GeleP, PetraultM, BastideM, LalouxC, MoreauC, BordetR, DevosD, DevedjianJC (2016) Ferroptosis, a newly characterized form of cell death in Parkinson’s disease that is regulated by PKC. Neurobiol Dis94, 169–178.
44.
AgrawalS, FoxJ, ThyagarajanB, FoxJH (2018) Brain mitochondrial iron accumulates in Huntington’s disease, mediates mitochondrial dysfunction, and can be removed pharmacologically. Free Radic Biol Med120, 317–329.
45.
ChenLJ, HambrightWS, NaR, RanQT (2015) Ablation of the ferroptosis inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron degeneration and paralysis. J Biol Chem290, 28097–28106.
46.
DuJ, ZhouY, LiYC, XiaJ, ChenYJ, ChenSF, WangX, SunWD, WangTT, RenXY, WangX, AnYH, LuK, HuWY, HuangSY, LiJH, TongXM, WangY (2020) Identification of Frataxin as a regulator of ferroptosis. Redox Biol32, 101483.
AytonS, FauxNG, BushAI (2017) Association of cerebrospinal fluid ferritin level with preclinical cognitive decline in APOE-epsilon4 carriers. JAMA Neurol74, 122–125.
DangTN, LimNK, GrubmanA, LiQX, VolitakisI, WhiteAR, CrouchPJ (2014) Increased metal content in the TDP-43(A315T) transgenic mouse model of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Front Aging Neurosci6, 15.
